Willison Nadia, Behnia-Willison Fariba, Aryan Pouria, Padhani Zahra Ali, Mirzaei Damabi Negin, Nguyen Tran, Yi Johnny, Dutta Rituparna, Abbott Derek
FBW Gynaecology Plus, Ashford, SA 5035, Australia.
Discipline of Biomedical Engineering, School of EME, The University of Adelaide, Adelaide, SA 5005, Australia.
J Clin Med. 2025 Aug 18;14(16):5832. doi: 10.3390/jcm14165832.
Platelet-rich plasma (PRP) therapy is a non-invasive, autologous treatment with regenerative potential in gynaecology beyond fertility applications. This review evaluates PRP in non-fertility-related gynaecological conditions affecting women's quality of life (QoL). Following PRISMA-ScR guidelines, we searched Embase, CINAHL, Web of Science, Scopus, CENTRAL, and MEDLINE for studies on PRP in conditions such as vulvar lichen sclerosus (VLS), vulvovaginal atrophy (VVA), sexual dysfunction (SD), stress urinary incontinence (SUI), and interstitial cystitis/bladder pain syndrome (IC/BPS). Of 3660 records screened, 43 studies (randomised controlled trials, quasi-experimental, cohort, and case series) were included. PRP improved symptoms and QoL in several conditions, particularly VLS and SD, and was generally well tolerated with minor adverse effects (e.g., injection-site pain, transient discomfort). Evidence for abnormal uterine bleeding (AUB) and pelvic organ prolapse (POP) was inconclusive. Considerable heterogeneity in preparation protocols and outcome measures limited cross-study comparison. PRP shows promise as a minimally invasive therapy for certain gynaecological conditions. Standardisation of preparation and administration, along with large-scale RCTs, is needed to determine long-term efficacy and safety.
富血小板血浆（PRP）疗法是一种非侵入性的自体治疗方法，在妇科领域具有再生潜力，其应用范围超出了生育领域。本综述评估了PRP在影响女性生活质量（QoL）的非生育相关妇科疾病中的应用。按照PRISMA-ScR指南，我们在Embase、CINAHL、科学网、Scopus、CENTRAL和MEDLINE中检索了关于PRP在诸如外阴硬化性苔藓（VLS）、外阴阴道萎缩（VVA）、性功能障碍（SD）、压力性尿失禁（SUI）以及间质性膀胱炎/膀胱疼痛综合征（IC/BPS）等疾病中的研究。在筛选的3660条记录中，纳入了43项研究（随机对照试验、准实验、队列研究和病例系列）。PRP改善了多种疾病的症状和生活质量，尤其是VLS和SD，并且总体耐受性良好，不良反应轻微（如注射部位疼痛、短暂不适）。关于异常子宫出血（AUB）和盆腔器官脱垂（POP）的证据尚无定论。制备方案和结局指标存在相当大的异质性，限制了跨研究比较。PRP作为某些妇科疾病的微创治疗方法显示出前景。需要对制备和给药进行标准化，并开展大规模随机对照试验，以确定其长期疗效和安全性。
